CMT Research Update: Pediatric Ankle And Gait Function

by | May 17, 2023 | 0 comments

HNF TRIAD Academic Partner Connecticut Children’s Publishes Results of CMT Pediatric Natural History Study to Better Understand Ankle Function and Gait 

HNF-funded research sought to determine how age and CMT type affect ankle strength in children. A detailed understanding of neuropathy progression is needed to guide informed treatments to improve or prevent a decline in gait function. 

Gait analysis and range of motion strength testing were used to evaluate children with both CMT1 and CMT2. The children with CMT1 had slightly more ankle strength that continued to increase with age until it plateaued at about 13 years, while the children with CMT2 were weaker and plateaued earlier but did not seem to get weaker with age. This highlights the importance of having an in-depth understanding of gait at the individual patient level using comprehensive gait analysis, including valid and reliable strength measures.

HNF continues to fund critical Pediatric Natural History Studies for CMT in preparation for clinical trials and to improve treatment outcomes. 

Are you a parent/caregiver of a child with CMT? Please participate in pediatric CMT research by joining today!


Learn more on this topic

Related Blog Posts

Hypotonia & CMT

Hypotonia & CMT

Hypotonia, or low muscle tone, can be caused by a variety of factors, including genetic conditions like Charcot-Marie-Tooth (CMT) disease

HNF is Reshaping Drug Repurposing for CMT

HNF is Reshaping Drug Repurposing for CMT

HNF has partnered with Rarebase, a public benefit precision medicine company that has screened a large library of FDA approved small molecules to identify candidates for various types of CMT. Their tech-enabled drug discovery platform is called Function™. There are many published discoveries on the genetic cause of many types of CMT, including an understanding of the basic mechanism of disease and potential targets for FDA-approved drug repurposing. It is this understanding that allows HNF and Rarebase to target the genetic root cause of CMT.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news